These points highlight the importance of carefully evaluating a patient’s medical and psychiatric background before initiating GLP-1 RA therapy and point to an urgent need for well-designed prospective clinical studies to clarify the mental health effects of these drugs in individuals with obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.